Imipenem/relebactam
Imipenem/relebactam is a topic covered in the Johns Hopkins ABX Guide.
To view the entire topic, please log in or purchase a subscription.
Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
FDA
- Infections caused by susceptible Gram-negative bacteria for patients who have limited or no alternative treatment options, who are ≥ 18 y/o; approval of these indications is based on limited clinical safety and efficacy data.
- Treatment of complicated urinary tract infections, including pyelonephritis (cUTI)
- Complicated intra-abdominal infections (cIAI)
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- MDR infections including bacteremia, pneumonia, osteomyelitis
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
FDA
- Infections caused by susceptible Gram-negative bacteria for patients who have limited or no alternative treatment options, who are ≥ 18 y/o; approval of these indications is based on limited clinical safety and efficacy data.
- Treatment of complicated urinary tract infections, including pyelonephritis (cUTI)
- Complicated intra-abdominal infections (cIAI)
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- MDR infections including bacteremia, pneumonia, osteomyelitis
There's more to see -- the rest of this entry is available only to subscribers.